Epidemiology of inhibitors in haemophilia A

Vox Sanguinis

Volumn 70, Issue SUPPL. 1, 1996, Pages 2-8

  Kreuz, W ^a   Escuriola Ettingshausen, C ^a   Martinez Saguer, I ^a   Gungor T ^a   Kornhuber, B ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING INHIBITOR;

ADOLESCENT; ADULT; CHILD; CONFERENCE PAPER; DISEASE SEVERITY; HEMOPHILIA A; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK;

EID: 0030058521     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.1996.tb01341.x     Document Type: Conference Paper

References (21)

1. Gill FM: The natural history of factor VIII inhibitors in patients with hemophilia A. Prog Clin Biol Res 1984;150:19-29.
2. Bray GL for the Recombinate® Study Group: Clinical experience with recombinant factor VIII (Recombinate®) in previously untreated patients with heomphilia A. XX International Congress of the World Federation of Hemophilia, Athens 1992, abstr 159, p 83.
3. Lusher JM, Arkin S, Abildgaard CF. Mannucci PM, Schwart RS and the Kogenate® Study Group. Recombinant factor (Kogenate®) in previously untreated subjects with hemophilia A - A three-year study. XX international Congress of the World Federation of Hemophilia. Athens 1992, abstr 159, p 94.
4. Rasi V, Ikkala E: Haemophiliacs with factor VIII inhibitors in Finland: Prevalence, incidence and outcome. Br J Haematol 1990;76: 369-371
5. Lusher JM, Arkin S, Abildgaard CF, Schwartz RS and the Kogenate® previously untreated patient Study Group- Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. N Engl J Med 1993;328: 453-439.
6. De Blasi R. Rocino A, Papa ML, Salerno E, Mastrullo L, De Blasi D: Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates. Thromb Haemost 1994;71:544-547.
7. Addiego J, Kapser C, Abildgaard C. Hilgartner M, Lusher J, Glader B, Aledort L: Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII. Lancet 1993;342. 462-464.
8. Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, Gungör T, Krackhardt B, Kornhuber B: Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992;339:594-598.
9. McMillan CW, Shapiro SS, Whithurst D, Hoyer LW, Rao V, Lazerson J and the Hemophilia Study Group: The natural history of factor VIII:C inhibitors in patients with hemophilia A. A National Cooperative Study: Observations on the Initial Development of Factor VIII:C Inhibitors. Blood 1988;71.344-348.
10. Lusher JM, Salzman PM and the Monoclate® Study Group: Viral safety and inhibitor development associated with factor VIII:C ultra-purified from plasma in haemophiliacs previously unexposed to factor VIII:C concentrate. Semin Haematol 1990;27:1-7.
11. Addiego J, Kasper C, Abildgaard C, Hilgartner M. Lusher M, Glader B, Aledort L: Inhibitors in factor VIII deficient hemophilia: Comparison of frequency based upon treatment. ASH, Anaheim. Blood 1992;80(suppl 1):231, abstr 913.
12. Lusher JM, Arkin S, Kreuz W, Mannucci PM, Pearce J and the Kogenate* Study Group: Inhibitor development in previously untreated hemophiliacs receiving rFVIII (Kogenate® - Is there an increased incidence? ASH, Denver. Blood 1991:78(suppl 1):57, abstr 217.
13. Sultan Y and the French Hemophilia Study Group. Prevalence of inhibitors in a population of 3,435 hemophilia patients in France. Thromb Haemost 1992;67:600-602.
14. Schwarzinger I. Pabinger I, Korninger C, Haschke F, Kundi M, Niessner H, Lechner K: Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates. Am J Hematol 1987;24:241-245.
15. Bray GL, Liu-Maruya S, Courter S, High K, Gomperts E and the Recombinate® Study Group: Experience with recombinant factor VIII (Recombinate®) in previously untreated patients with severe hemophilia A ASH, Anaheim. Blood 1992;80(suppl 1):229. abstr 908.
16. Addiego J, Kasper C, Abildgaar C. Hilgartner M, Lusher J. Glader B, Aledort L: Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII. Lancet 1993;342: 462-464.
17. Ljung R, Petrini P, Lindgren A, Tengborn L, Nilsson I: Factor VIII and factor IX inhibitors in haemophiliacs (letter). Lancet 1992;339:1550.
18. Lusher JM: Viral safety and inhibitor development associated with monoclonal antibody-purified FVIII: C. Ann Hematol 1991;63:138-141.
19. Bray G, Lee M, Buckwalter C, Lynes M, Courter S. Gomperts E for the Recombinate® Study Group: Use of recombinant factor VIII (Recombinate®) in previously untreated patients with hemophilia A. XXI International Congress of the World Federation of Hemophilia, Mexico City 1994, abstr 107.
20. Kreuz W, Martinez-Saguar I, et al. Inhibitor-inzidenz bei erstbehandelten Hämophilien, in Scharrer I (ed): Erstes deutsches Kogenate® Symposium Klinische Erfahrung und Sicherheitsaspekte. Lengerich, Pabst-Verlag, 1994, pp 126-133.
21. Aledort L. Proposal for a standardized protocol for PUP studies to screen for inhibitor formation SSC for FVIII and LX of the International Society on Thrombosis and Haemostasis, Munich 1992.